CytomX Therapeutics, Inc. (CTMX)
Data as of , from SEC Form 4 filings.
See up to 3 months of CTMX. The 7-day demo opens the 1M and 3M ranges and puts CTMX on your watchlist.
Start 7-day demoLatest CTMX insider trades
Christopher Ogden - OfficerOpen-market sale$5K- Yu-Waye Chu - OfficerOpen-market sale$137K
About CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- SOUTH SAN FRANCISCO, CA
- 69
- 2015
- XNAS
CTMX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 3 | 668,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CTMX insider transactions (Form 4)
3726 Form 4 filings on record, the earliest from Jun 11, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Alejandra Carvajal - Officer | Grant or award | Common Stock | 100,000 footnote F1 | $0.00 | - | |
| Alejandra Carvajal - Officer | Grant or award | Stock Option (Right to Buy) | 450,000 | $0.00 | - | |
| ||||||
| Charles S. Fuchs - Director | Grant or award | Stock Option (Right to Buy) | 118,000 | $0.00 | - | |
 Zhen Su | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
| Matthew P. Young | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
| Mani Mohindru | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
| James R. Meyers | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
| Halley E. Gilbert | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
 Alan Ashworth | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
| Elaine V. Jones | Grant or award | Stock Option (Right to Buy) | 59,000 | $0.00 | - | |
| Christopher Ogden - Officer | Open-market sale | Common Stock | 1,624 | $3.05 | $5K | |
| Yu-Waye Chu - Officer | Open-market sale | Common Stock | 21,279 | $6.42 | $137K | |
| Sean A. McCarthy - Officer | Open-market sale | Common Stock | 118,969 | $6.42 | $764K | |
| Marcia Belvin - Officer | Open-market sale | Common Stock | 31,492 | $6.42 | $202K | |
| Christopher Ogden - Officer | Open-market sale | Common Stock | 19,323 | $6.42 | $124K | |
| Rachael Lester - Officer | Grant or award | Common Stock | 20,000 footnote F1 | $0.00 | - | |
| Rachael Lester - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Rachael Lester - Officer | Grant or award | Performance Stock Units (PSUs) | 50,000 | $0.00 | - | |
| ||||||
| Yu-Waye Chu - Officer | Grant or award | Common Stock | 75,000 footnote F1 | $0.00 | - | |
| Yu-Waye Chu - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| ||||||
| Marcia Belvin - Officer | Grant or award | Common Stock | 60,000 footnote F1 | $0.00 | - | |
| Marcia Belvin - Officer | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| ||||||
| Christopher Ogden - Officer | Grant or award | Common Stock | 90,000 footnote F1 | $0.00 | - | |
| Christopher Ogden - Officer | Grant or award | Stock Option (Right to Buy) | 325,000 | $0.00 | - | |
| ||||||
| Sean A. McCarthy - Officer | Grant or award | Common Stock | 210,000 footnote F1 | $0.00 | - | |
| Sean A. McCarthy - Officer | Grant or award | Stock Option (Right to Buy) | 980,000 | $0.00 | - | |
| ||||||
| Sean A. McCarthy - Officer | Open-market sale | Class A Common Stock | 101,793 | $4.54 footnote F2 | $462K | |
| ||||||
| Rachael Lester - Officer | Grant or award | Stock Option (Right to Buy) | 650,000 | $0.00 | - | |
| Sean A. McCarthy - Officer | Grant or award | Stock Option (Right to Buy) | 570,000 | $0.00 | - | |
| Sean A. McCarthy - Officer | Grant or award | Performance Stock Units (PSUs) | 285,000 | $0.00 | - | |
| Yu-Waye Chu - Officer | Grant or award | Stock Option (Right to Buy) | 87,500 | $0.00 | - | |
| Yu-Waye Chu - Officer | Grant or award | Performance Stock Units (PSUs) | 43,750 | $0.00 | - | |
| Christopher Ogden - Officer | Grant or award | Stock Option (Right to Buy) | 78,250 | $0.00 | - | |
| Christopher Ogden - Officer | Grant or award | Performance Stock Units (PSUs) | 39,150 | $0.00 | - | |
| Marcia Belvin - Officer | Grant or award | Stock Option (Right to Buy) | 36,300 | $0.00 | - | |
| Marcia Belvin - Officer | Grant or award | Performance Stock Units (PSUs) | 18,150 | $0.00 | - | |
| Elaine V. Jones | Grant or award | Stock Option (Right to Buy) | 38,000 | $0.00 | - | |
CTMX insider trading FAQ
What is the latest insider trade for CTMX?
CytomX Therapeutics, Inc. (CTMX) had 2 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for CTMX runs to 26 Form 4 filings, the earliest from 2025-06-11. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CTMX stock?
No insider purchases of CTMX were filed in the last 90 days.
How many insiders are selling CTMX stock?
No insider sales of CTMX were filed in the last 90 days. 6 sales are on record for this company.
Where can I see CTMX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CTMX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Alejandra Carvajal view on EDGAR
- - Charles S. Fuchs view on EDGAR
- - Zhen Su view on EDGAR
- - Matthew P. Young view on EDGAR
- - Mani Mohindru view on EDGAR
- - James R. Meyers view on EDGAR
- - Halley E. Gilbert view on EDGAR
- - Alan Ashworth view on EDGAR
- - Elaine V. Jones view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where CTMX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CTMX with a 7-day demo
- CTMX on your watchlist
- Every CTMX Form 4 filing on record
- Up to 3 months of CTMX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
